D3 Bio Secures $108 Million in Series B Financingto Advance Global Clinical Programs

Shanghai, China – December 08, 2025 –D3 Bio, a global clinical-stage biotechnology company dedicated to thediscovery and development of transformative oncology therapeutics, todayannounced the successful completion of a $108 million Series B financing round.

Thefunding round was backed by a distinguished group of investors, including IDGCapital and SongQing Capital. Existing investors —WuXi AppTec's CorporateVenture Fund, Temasek, HSG, MPCi, and Medicxi — also contributed to the round.The robust involvement from both new and current investors highlightswidespread confidence in D3 Bio's innovative pipeline and its globaldevelopment strategy.

Proceedsfrom this financing will primarily support the planned global Phase III pivotalprogram for the company's lead asset, elisrasib (D3S-001). These pivotal trialswill assess elisrasib as both a monotherapy and in combination therapies forKRAS G12C-mutant cancers across key countries and regions, includingtheUnited States,China, and the European Union, to facilitate globalregulatory submissions.

Furthermore, the funding will facilitateongoing development of D3 Bio's comprehensive pipeline of targeted andimmuno-oncology programs, which are centred on innovative mechanisms withfirst-in-class or best-in-class potential.

Dr. George Chen, Founder, Chairman,and CEO of D3 Bio, stated, "The completion of our Series B financingdemonstrates the strong confidence our investors place in our vision,scientific approach, business operations, and global development capabilities.This funding enables us to advance our lead program into late-stage clinicaltrials and further expand our pipeline of innovative therapies designed tobenefit patients globally."

Dr. Antoine Yver, Member of the Boardof Directors and Scientific Committee of D3 Bio, stated, "This financingdemonstrates that the swift and effective pursuit of the best- orfirst-in-class science is meaningful to society, and validates D3 Bio's leadinginnovation, scientific vision and development strategy. It also highlights theunique potential of elisrasib for individuals affected by KRAS G12C-mutantcancers."

About D3 Bio

D3 Bio is a global biotechnology companyfocused on the discovery, development, and registration of new medicines inoncology and immunology. The company's discovery and development platformsleverage proprietary clinical insight and biomarker strategies to create noveland clinically meaningful therapies for patients in need. D3 Bio's oncologyprograms target driver mutations or critical immune pathways and are designedto have first-in-class or best-in-class potential. D3 Bio owns global rightsfor all of its programs.

Formore information, please visit www.d3bio.com.

‍

Media Contact:
Chris Yan
Head,Capital Market and Investor Relation
‍chris.yan@d3bio.com
Shanghai, China